Congailure

Congestive Cardiac Failure Dr. R. Senthil Kumar

Introduction to Heart Failure ,[object Object],[object Object],[object Object],[object Object],[object Object]

Recent Advances Vs Reality ,[object Object],[object Object],[object Object],[object Object]

Acute Vs Chronic HF ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Cardiac Vs Noncardiac targets ,[object Object],[object Object],[object Object]

Compensation in HF ,[object Object],[object Object],[object Object],[object Object]

Compensation contd.. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Consequences of hyperadrenergic state ,[object Object],[object Object],[object Object],[object Object]

Pathophysiology ,[object Object]

Therapeutic Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Goals and drug therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Signs and symptoms ,[object Object],[object Object],[object Object],[object Object]

Diuretics ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Renin angiotensin system ,[object Object],[object Object],[object Object],[object Object]

MOA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Advantages ,[object Object],[object Object],[object Object],[object Object]

ADR ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Other Vasodilators: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Inotropes ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Cardiac glycosides ,[object Object],[object Object],[object Object],[object Object]

Pck ,[object Object],[object Object],[object Object],[object Object],[object Object]

Pck ,[object Object],[object Object],[object Object],[object Object]

MOA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Additional MOA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Electrophysiological effects on the heart

Uses ,[object Object],[object Object],[object Object],[object Object]

ADR ,[object Object],[object Object],[object Object],[object Object]

Signs of digoxin toxicity ,[object Object],[object Object],[object Object]

Factors increasing the possibility of digoxin toxicity ,[object Object],[object Object]

Management ,[object Object],[object Object],[object Object]

[object Object],What could it be???

Dopamine ,[object Object],[object Object]

Dobutamine ,[object Object],[object Object]

PDE inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

MOA ,[object Object],[object Object],[object Object]

Current status ,[object Object],[object Object],[object Object],[object Object],[object Object]

ADR ,[object Object],[object Object],[object Object]

(BNP)-Niseritide ,[object Object],[object Object],[object Object]

BNP contd.. ,[object Object],[object Object],[object Object]

Beta blockers ,[object Object],[object Object],[object Object],[object Object]

Management of Chronic HF (combination of drugs) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Management of acute HF ,[object Object],[object Object],[object Object],[object Object],[object Object]

Congailure

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (20)

Similaire à Congailure

Similaire à Congailure (20)

Plus de Flavio Guzmán

Plus de Flavio Guzmán (20)

Dernier

Dernier (20)

Congailure